Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas

  • STATUS
    Recruiting
  • days left to enroll
    23
  • participants needed
    25
  • sponsor
    Assistance Publique Hopitaux De Marseille
Updated on 25 January 2021
renal function
mekinist
grade iii meningioma

Summary

Aggressive growing meningiomas resistant to multiple surgeries and radiotherapy constitute an unmet pharmaceutical need in neurooncology, leading to a fatal issue within a few months. Grade II-III meningiomas progression-free survival (PFS) 6 is at 10-15%. Median PFS grade III meningioma is approximate 3 years.

Alpelisib is a well-tolerated Phosphoinositide 3-kinase (Pi3K) specific inhibitor. However, phosphatidylinositol-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) inhibition does not induce apoptosis in vitro and induces an antiproliferative effect without any radiologic response in most treated patients.

Trametinib, a mekinist (MEK) inhibitor is currently used in combined treatment for recurrent melanomas in clinical practice with a good clinical tolerance at 1-2 mg daily. In vitro, on meningioma primary cell culture, Trametinib induces cell apoptosis via caspase activity.

These results strongly suggest the relevance to combine Alpelisib and Trametinib in aggressive and recurrent meningiomas.

Alpelisib and Trametinib combination has not been studied to date, despite each drugs have been separately studied in phase 3.

Multicenter, open label, dose-finding phase I study of Alpelisib in combination with Trametinib administered at a fixed dose (1.5 mg daily), both drugs will be administered daily. Starting dose of Alpelisib will be 160mg/day and will be increased to 200mg/day or decreased to 120mg/day depending of grade 3-4 adverse events occurrence, to determine maximal tolerated dose (MTD) and recommended dose.

Primary Objective is to determine the safety profile and tolerability of Alpelisib and Trametinib given in combination in patients with aggressive and refractory meningiomas in terms of Dose-Limiting Toxicities (DLT, assessed during cycle 1).

Details
Condition Meningioma, Meningiomas, Meningiomas
Treatment MRI, Blood sample, Trametinib, Alpelisib
Clinical Study IdentifierNCT03631953
SponsorAssistance Publique Hopitaux De Marseille
Last Modified on25 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically proven meningioma grade I, II and III
Progression is defined as growing meningiomas on 2 different Magnetic Resonance Imaging (MRI) 3 to 6 months apart
Patients must have failed surgery, and not amenable to a new curative intended surgery
Patients must have failed radiotherapy and/or radiosurgery
Patients who have given their written consent
No contra indication to Alpelisib and Trametinib
No receiving other investigational agents
Written informed consent
Adequate bone marrow function
Adequate liver function as shown by
Adequate renal function

Exclusion Criteria

Contra indication to Alpelisib and Trametinib
Women of child-bearing age who are using no effective means of contraception
Pregnant or breast-feeding women
Patients receiving other investigational agents
Known intolerance or hypersensitivity to Alpelisib and Trametinib
Uncontrolled diabetes mellitus
Patients who have any severe and uncontrolled medical condition
Patients receiving chronic treatment with immunosuppressives
Patients with a known history of HIV seropositivity
Patients who have a history of another primary malignancy less than or equal to 3 years, with
the exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note